Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AARDNASDAQ:AMRNNASDAQ:ICCCNASDAQ:OCGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAARDAardvark Therapeutics$11.95+2.1%$9.45$4.88▼$19.58$253.84MN/A103,165 shs33,708 shsAMRNAmarin$11.85$10.24$7.08▼$16.60$245.38M0.7174,581 shs50,224 shsICCCImmuCell$6.68-1.0%$5.57$3.34▼$7.01$60.37M0.2322,227 shs15,762 shsOCGNOcugen$0.95+7.4%$0.74$0.52▼$1.98$278.28M4.214.51 million shs11.06 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAARDAardvark Therapeutics+2.14%+16.02%+14.35%+17.97%+1,194,999,900.00%AMRNAmarin0.00%+1.46%+15.22%+11.79%-16.31%ICCCImmuCell-1.04%+6.71%+30.21%+28.34%+47.95%OCGNOcugen+7.41%+14.23%+33.24%+56.16%-47.35%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAARDAardvark TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAMRNAmarin0.2339 of 5 stars1.02.00.00.02.10.00.0ICCCImmuCell0.2495 of 5 stars0.03.00.00.02.00.00.0OCGNOcugen1.0028 of 5 stars3.50.00.00.02.00.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAARDAardvark Therapeutics 3.00Buy$31.25161.51% UpsideAMRNAmarin 2.00Hold$7.00-40.93% DownsideICCCImmuCell 0.00N/AN/AN/AOCGNOcugen 3.00Buy$6.00529.66% UpsideCurrent Analyst Ratings BreakdownLatest ICCC, OCGN, AMRN, and AARD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2025AARDAardvark TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$21.00 ➝ $20.005/12/2025OCGNOcugenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$8.00 ➝ $7.005/12/2025OCGNOcugenChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.004/17/2025AMRNAmarinThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSell ➝ Sell$20.00 ➝ $7.004/1/2025AARDAardvark TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$21.00 ➝ $21.004/1/2025AARDAardvark TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$50.00 ➝ $50.003/27/2025AARDAardvark TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$22.00 ➝ $26.003/10/2025AARDAardvark TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$29.003/10/2025AARDAardvark TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$22.003/10/2025AARDAardvark TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$21.003/10/2025AARDAardvark TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$50.00(Data available from 6/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAARDAardvark TherapeuticsN/AN/AN/AN/AN/AN/AAMRNAmarin$214.11M1.15N/AN/A$1.35 per share8.78ICCCImmuCell$27.30M2.21N/AN/A$3.23 per share2.07OCGNOcugen$4.52M61.54N/AN/A$0.16 per share5.96Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAARDAardvark TherapeuticsN/AN/A0.00∞N/AN/AN/AN/AN/AAMRNAmarin-$59.11M-$3.64N/AN/AN/A-16.33%-7.22%-4.96%7/30/2025 (Estimated)ICCCImmuCell-$5.78M-$0.07N/A∞N/A-15.99%-15.32%-8.81%8/12/2025 (Estimated)OCGNOcugen-$63.08M-$0.19N/AN/AN/A-532.51%-154.75%-90.79%8/14/2025 (Estimated)Latest ICCC, OCGN, AMRN, and AARD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025N/AAARDAardvark Therapeutics-$0.70-$0.71-$0.01-$0.71N/AN/A5/14/2025Q1 2025ICCCImmuCellN/A$0.16N/A$0.16N/A$8.07 million5/9/2025Q1 2025OCGNOcugen-$0.06-$0.05+$0.01-$0.05N/A$1.48 million5/7/2025Q1 2025AMRNAmarin-$0.06-$0.04+$0.02-$0.04$50.75 millionN/A3/12/2025Q4 2024AMRNAmarin-$1.20-$2.40-$1.20-$0.12$32.37 million$62.31 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAARDAardvark TherapeuticsN/AN/AN/AN/AN/AAMRNAmarinN/AN/AN/AN/AN/AICCCImmuCellN/AN/AN/AN/AN/AOCGNOcugenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAARDAardvark TherapeuticsN/AN/AN/AAMRNAmarinN/A3.232.11ICCCImmuCell0.363.111.44OCGNOcugen0.042.582.58Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAARDAardvark TherapeuticsN/AAMRNAmarin22.25%ICCCImmuCell13.47%OCGNOcugen10.27%Insider OwnershipCompanyInsider OwnershipAARDAardvark TherapeuticsN/AAMRNAmarin3.30%ICCCImmuCell6.60%OCGNOcugen4.42%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAARDAardvark Therapeutics1821.70 millionN/AN/AAMRNAmarin36020.71 million402.62 millionOptionableICCCImmuCell709.04 million8.32 millionNot OptionableOCGNOcugen80292.03 million278.82 millionOptionableICCC, OCGN, AMRN, and AARD HeadlinesRecent News About These CompaniesOcugen signs term sheet for korean licensing of OCU400 gene therapyJune 5 at 10:19 PM | ophthalmologytimes.comOcugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in KoreaJune 5 at 7:02 AM | globenewswire.comJane Street Group LLC Purchases 357,891 Shares of Ocugen, Inc. (NASDAQ:OCGN)June 1, 2025 | marketbeat.comOcugen’s OCU410ST receives Rare Pediatric Disease Designation for the treatment of ABCA4-associated retinopathiesMay 27, 2025 | ophthalmologytimes.comOcugen wins FDA rare pediatric disease status for genetic eye disorder treatmentMay 27, 2025 | msn.comOcugen, Inc. Receives FDA Rare Pediatric Disease Designation for OCU410ST in Treatment of ABCA4-Associated RetinopathiesMay 27, 2025 | quiverquant.comOcugen Announces Rare Pediatric Disease Designation Granted for OCU410ST—Modifier Gene Therapy for the Treatment of Stargardt DiseaseMay 27, 2025 | globenewswire.comNoble Financial Predicts Ocugen's Q2 Earnings (NASDAQ:OCGN)May 16, 2025 | marketbeat.comThe Analyst Verdict: Ocugen In The Eyes Of 5 ExpertsMay 14, 2025 | nasdaq.comOcugen (NASDAQ:OCGN) Price Target Cut to $7.00 by Analysts at HC WainwrightMay 14, 2025 | marketbeat.comOcugen's (OCGN) "Buy" Rating Reiterated at Chardan CapitalMay 14, 2025 | marketbeat.comOcugen (NASDAQ:OCGN) Releases Earnings Results, Beats Estimates By $0.01 EPSMay 13, 2025 | marketbeat.comOcugen Reports Progress in Q1 2025 with Advancements in Gene TherapyMay 13, 2025 | msn.com1OCGN : The Analyst Verdict: Ocugen In The Eyes Of 5 ExpertsMay 13, 2025 | benzinga.comOcugen, Inc. (NASDAQ:OCGN) Q1 2025 Earnings Call TranscriptMay 10, 2025 | msn.comOcugen Stock Rises On Better-Than-Feared Q1 Loss: Retail Turns BullishMay 9, 2025 | msn.comOcugen, Inc. (OCGN) Q1 2025 Earnings Call TranscriptMay 9, 2025 | seekingalpha.comOcugen Provides Business Update with First Quarter 2025 Financial ResultsMay 9, 2025 | globenewswire.comA Look at Ocugen's Upcoming Earnings ReportMay 9, 2025 | benzinga.comOcugen (OCGN) Projected to Post Earnings on FridayMay 6, 2025 | marketbeat.comOcugen to Host Q1 2025 Earnings Call and Business Update on May 9May 5, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeICCC, OCGN, AMRN, and AARD Company DescriptionsAardvark Therapeutics NASDAQ:AARD$11.95 +0.25 (+2.14%) As of 06/5/2025 04:00 PM EasternAardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.Amarin NASDAQ:AMRN$11.85 0.00 (0.00%) Closing price 06/5/2025 04:00 PM EasternExtended Trading$11.82 -0.03 (-0.21%) As of 06/5/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.ImmuCell NASDAQ:ICCC$6.68 -0.07 (-1.04%) Closing price 06/5/2025 03:50 PM EasternExtended Trading$6.74 +0.06 (+0.82%) As of 06/5/2025 04:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.Ocugen NASDAQ:OCGN$0.95 +0.07 (+7.41%) Closing price 06/5/2025 04:00 PM EasternExtended Trading$0.95 0.00 (-0.20%) As of 06/5/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio? Is Meta Plotting a Stablecoin Comeback Years After Libra's Flop? NVIDIA Regains Top Spot; FOMO Is Why It Will Continue to Rise Robinhood Stock Keeps Giving Investors Reasons To Buy Hims & Hers Stock: Buy the Dip or Wait It Out? Boeing: Analyst Upgrades & Order Boom Signal Clearer Skies CrowdStrike Stock Dips on Guidance Miss: It May Rebound Fast A New All-Time High Is Coming Soon for Credo Technology Group Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
